The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present Phase 1/2 clinical data and Phase 3 ...

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...

Codexis has agreed to manufacture 50 grams of siRNA using its proprietary ECO Synthesis manufacturing platform to support ...